Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
LNLantheus Holdings, Inc. logo

Lantheus Holdings, Inc. (LNTH)

NASDAQ Global Market · Currency in USD
$99.80 ▼ -0.30 (-0.30%)
At close: Oct 23, 4:00 PM ET. Market closed.
$99.61 ▼ -0.19 (-0.19%)
Pre-market: Oct 26, 5:24 AM ET

Summary

Previous Close
$100.10
Open
$99.97
Day's Range
$99.80 – $100.09
52 Week Range
$50.16 – $111.86
Volume
877,043
Avg. Volume
1,264,768
Market Cap
$6.52B
Beta (5Y Monthly)
-0.06
PE Ratio (TTM)
23.71
EPS (TTM)
$4.23
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$102.65

Profile: Lantheus Holdings, Inc.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-time employees
1,193
CEO
Mary Anne Heino

Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate $1.26 · Revenue est. $360.82M
DateEst.Actual
Aug 6, 2026$1.30$1.55Beat
May 7, 2026$1.25$1.46Beat
Feb 26, 2026$1.18$1.67Beat
Nov 6, 2025$1.27$1.27Beat
Aug 6, 2025$1.64$1.57Miss
May 7, 2025$1.68$1.53Miss

Analyst view

Consensus price target
$102.65 ▲ +2.9%
Range $94.00 – $109.00
Rating: Buy
Buy 53% · Hold 47% · Sell 0%

Similar stocks

Get free alerts on LNTH and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.